Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...

LONDON/COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk's ... takes to approve pharma plants in the United States, as part of new regulations to encourage domestic manufacturing.

Trump signed an executive order on Monday that aims to reduce the time it takes to approve pharma plants in the United States, as part of new regulations to encourage domestic manufacturing. Novo ...

Investing.com -- Novo Nordisk (NYSE: NVO )’s CFO, Karsten Munk Knudsen, expressed doubts on Wednesday about the potential impact of U.S. President Donald Trump’s recent executive order on the ...